Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H6NO2.Na |
Molecular Weight | 159.1178 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC1=CC=C(C=C1)C([O-])=O
InChI
InChIKey=XETSAYZRDCRPJY-UHFFFAOYSA-M
InChI=1S/C7H7NO2.Na/c8-6-3-1-5(2-4-6)7(9)10;/h1-4H,8H2,(H,9,10);/q;+1/p-1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14850772 | https://www.ncbi.nlm.nih.gov/pubmed/14774206 | https://www.ncbi.nlm.nih.gov/pubmed/14779043 | https://www.ncbi.nlm.nih.gov/pubmed/18150079 | https://www.ncbi.nlm.nih.gov/pubmed/21402476
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14850772 | https://www.ncbi.nlm.nih.gov/pubmed/14774206 | https://www.ncbi.nlm.nih.gov/pubmed/14779043 | https://www.ncbi.nlm.nih.gov/pubmed/18150079 | https://www.ncbi.nlm.nih.gov/pubmed/21402476
AMINOBENZOATE SODIUM is a salt of Aminobenzoic acid. Aminobenzoic acid is an intermediate in the synthesis of folate by bacteria, plants, and fungi. Many bacteria, including those found in the human intestinal tract such as E. coli, generate Aminobenzoic acid from chorismate by the combined action of the enzymes 4-amino-4-deoxychorismate synthase and 4-amino-4-deoxychorismate lyase. Plants produce Aminobenzoic acid in their chloroplasts, and store it as a glucose ester (pABA-Glc) in their tissues. Humans lack the enzymes to convert Aminobenzoic acid to folate, so require folate from dietary sources such as green leafy vegetables. In humans, Aminobenzoic acid is considered nonessential and, although it has been referred to historically as "vitamin Bx", is no longer recognized as a vitamin, because most people have colon bacteria that generate Aminobenzoic acid. The potassium salt is used as a drug against fibrotic skin disorders, such as Peyronie's disease, under the trade name Potaba.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2013 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26288086 |
|||
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21402476 |
8400.0 nM [Ki] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21402476 |
8130.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Pabalate Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
9 g multiple, oral Studied dose Dose: 9 g Route: oral Route: multiple Dose: 9 g Sources: |
unhealthy, 45 years n = 1 Health Status: unhealthy Condition: Peyronie’s disease Age Group: 45 years Sex: M Population Size: 1 Sources: |
Disc. AE: DRESS syndrome... AEs leading to discontinuation/dose reduction: DRESS syndrome Sources: |
150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Other AEs: Skin infection, Oral candidiasis... Other AEs: Skin infection (8.3%) Sources: Oral candidiasis (25%) Pneumonia (8.3%) Cushing's syndrome (8.3%) Steroid acne (8.3%) Diabetes mellitus (16.7%) Anaemia (8.3%) Neurosis (8.3%) |
2 g 3 times / day multiple, oral Studied dose Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Co-administed with:: tamsulosin Sources: finasteride |
unhealthy, 70 years n = 1 Health Status: unhealthy Condition: Peyronie’s disease Age Group: 70 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hepatitis acute... AEs leading to discontinuation/dose reduction: Hepatitis acute Sources: |
3 g 4 times / day multiple, oral Recommended Dose: 3 g, 4 times / day Route: oral Route: multiple Dose: 3 g, 4 times / day Sources: |
unhealthy, mean age 49 years n = 51 Health Status: unhealthy Condition: Peyronie’s disease Age Group: mean age 49 years Sex: M Population Size: 51 Sources: |
Disc. AE: Gastrointestinal disorders, Pruritus... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (7.8%) Sources: Pruritus (2%) Fever (2%) Chills (2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
DRESS syndrome | Disc. AE | 9 g multiple, oral Studied dose Dose: 9 g Route: oral Route: multiple Dose: 9 g Sources: |
unhealthy, 45 years n = 1 Health Status: unhealthy Condition: Peyronie’s disease Age Group: 45 years Sex: M Population Size: 1 Sources: |
Diabetes mellitus | 16.7% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Oral candidiasis | 25% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Anaemia | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Cushing's syndrome | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Neurosis | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Pneumonia | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Skin infection | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Steroid acne | 8.3% | 150 mg 1 times / day multiple, intramuscular (mean) Studied dose Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: prednisolone(36.1 mg; daily) Sources: |
unhealthy, 56.6 years n = 12 Health Status: unhealthy Condition: pemphigus vulgaris Age Group: 56.6 years Sex: M+F Population Size: 12 Sources: |
Hepatitis acute | Disc. AE | 2 g 3 times / day multiple, oral Studied dose Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Co-administed with:: tamsulosin Sources: finasteride |
unhealthy, 70 years n = 1 Health Status: unhealthy Condition: Peyronie’s disease Age Group: 70 years Sex: M Population Size: 1 Sources: |
Chills | 2% Disc. AE |
3 g 4 times / day multiple, oral Recommended Dose: 3 g, 4 times / day Route: oral Route: multiple Dose: 3 g, 4 times / day Sources: |
unhealthy, mean age 49 years n = 51 Health Status: unhealthy Condition: Peyronie’s disease Age Group: mean age 49 years Sex: M Population Size: 51 Sources: |
Fever | 2% Disc. AE |
3 g 4 times / day multiple, oral Recommended Dose: 3 g, 4 times / day Route: oral Route: multiple Dose: 3 g, 4 times / day Sources: |
unhealthy, mean age 49 years n = 51 Health Status: unhealthy Condition: Peyronie’s disease Age Group: mean age 49 years Sex: M Population Size: 51 Sources: |
Pruritus | 2% Disc. AE |
3 g 4 times / day multiple, oral Recommended Dose: 3 g, 4 times / day Route: oral Route: multiple Dose: 3 g, 4 times / day Sources: |
unhealthy, mean age 49 years n = 51 Health Status: unhealthy Condition: Peyronie’s disease Age Group: mean age 49 years Sex: M Population Size: 51 Sources: |
Gastrointestinal disorders | 7.8% Disc. AE |
3 g 4 times / day multiple, oral Recommended Dose: 3 g, 4 times / day Route: oral Route: multiple Dose: 3 g, 4 times / day Sources: |
unhealthy, mean age 49 years n = 51 Health Status: unhealthy Condition: Peyronie’s disease Age Group: mean age 49 years Sex: M Population Size: 51 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14779043
Sodium para-aminobenzoate has been administered orally in doses of 2 grams every two hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21402476
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO2 hydration activity. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10–20 mM Hepes (pH 7.5, for the a-CAs) or TRIS (pH 8.3, for the b-CAs) as buffers, and 20 mM Na2SO4 or 20 mM NaClO4 (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of AMINOBENZOATE SODIUM (1 mM) were prepared in distilled–deionized water and dilutions up to 0.1 nM were done thereafter with distilled–deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E–I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes from Lineweaver–Burk plots, as reported earlier, and represent the mean from at least three different determinations.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000078101
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
DBSALT002731
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
1019767
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
SUB15271MIG
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
517441
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
75UI7QUZ5J
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
DTXSID8060296
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
555-06-6
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
235493
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL542
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
209-080-3
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
75UI7QUZ5J
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY | |||
|
C77315
Created by
admin on Fri Dec 15 15:13:10 GMT 2023 , Edited by admin on Fri Dec 15 15:13:10 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD